生长抑素联合乌司他丁治疗消化道出血的Meta分析

目的 系统评价生长抑素联合乌司他丁治疗消化道出血的有效性和安全性。方法 计算机检索中国知网、维普、万方、CBM、PubMed、Cochorane library、Embase数据库,搜集有关生长抑素联合乌司他丁治疗消化道出血的随机对照试验。使用Revman 5.3软件进行Mete分析。结果 共纳入16项研究,1466例患者。结果显示,在总有效率[RR=1.24,95%CI(1.19～1.31),P <0.000 01]、白细胞介素-2[SMD=1.10,95%CI(0.38～1.81),P=0.003]、白细胞介素-6[SMD=-3.40,95%CI(-4.69～-2.12),P <0.000 01]、白细胞介素-10[SMD=2.77,95%CI(1.66～3.87),P <0.000 01]、肿瘤坏死因子-α[SMD=-2.56,95%CI(-3.26～-1.87),P<0.000 01]、住院时间[SMD=-1.75,95%CI(-2.24～-1.26),P<0.000 01]、消化道出血时间[SMD=-3.55,95%CI(-4.11～-2.99)...

Meta analysis of somatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding

ObjectiveTo systematically evaluate the efficacy and safety of somatostatin combined with ulinastatin in the treatment of gastrointestinal hemorrhage. MethodsCNKI, VIP, Wanfang, CBM database, PubMed, Cochrane Library, EMBase were searched to collect randomized controlled trials of somatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding.Mete analysis was performed using Revman 5.3 software. ResultsA total of 16 studies involving 1466 patients were included.The results showed that somatostatin combined with ulinastatin was better than somatostatin alone in the total effective rate(RR=1.24, 95% CI: 1.19-1.31, P<0.000 01), interleukin-2(SMD=1.10, 95% CI: 0.38-1.81, P=0.003), interleukin-6(SMD=-3.40, 95% CI: -4.69--2.12, P<0.000 01), interleukin-10(SMD=2.77, 95% CI: 1.66-3.87, P<0.000 01), tumor necrosis factor-α(SMD=-2.56, 95% CI: -3.26--1.87, P<0.000 01), hospitalization time(SMD=-1.75, 95% CI: -2.24--1.26, P<0.000 01)and gastrointestinal hemostasis time(SMD=-3.55, 95% CI: -4.11--2.99, P<0.000 01). There was no statistically significant difference in the incidence of adverse reactions between the two groups(SMD=0.79, 95% CI: 0.47-1.32, P=0.38), and both were lower. ConclusionSomatostatin combined with ulinastatin in the treatment of gastrointestinal bleeding is safe and effective, but it needs more high-quality clinical trials to verify.